April 17 (Reuters) - OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.
The trial was testing the combination of Oncomed’s tarextumab and chemotherapy, compared with chemotherapy and a placebo. The main goal was to slow the progression of the disease.
Last week, the company said it would discontinue a trial testing its experimental drug, demcizumab, as an initial treatment for advanced pancreatic cancer. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D‘Silva)